Compare Novartis AG (NVS) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Union Pacific Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Union Pacific Corporation trades at $293.9 (market cap $175.89B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | UNP | |
|---|---|---|
Market Cap | $290.25B | $175.89B |
Sector | Health | Industrials |
52-Week High | $168.62 | $301.75 |
52-Week Low | $113.50 | $214.91 |
Enterprise Value | $330.27B | $206.36B |
Dividend Yield | 3.17% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Union Pacific (UNP) trades at $293.13, down 2.86% on the day, with technical indicators showing a bullish trend but overbought RSI levels. The company maintains strong profitability with a 29.2% net margin and 40.69% ROE, supported by consistent cash flow from operations of $9.29B in 2025. Recent news highlights Q2 2026 earnings anticipation and progress on the proposed Norfolk Southern merger, while a class action lawsuit presents a legal overhang.
Outlook remains positive with analyst consensus pointing to 6% upside to a $311.07 price target, though regulatory hurdles for the merger and economic sensitivity pose risks. The stock offers a solid dividend yield and operational resilience, but investors should weigh earnings performance against valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
